Analyst Reaffirms Positive Outlook on Enovix with Increased Target Price
On July 27, 2023, Tim Moore, an analyst at EF Hutton, reaffirmed his positive outlook on Enovix (NASDAQ:ENVX) and increased ...
Tag: CELU
Celularity Inc.: A Promising Investment Opportunity in Biotechnology
May 29, 2023 - Celularity Inc. has been in the spotlight of late, and for good reason. The clinical-stage biotechnology ...
Celularity’s Placental-Derived Cell Therapies Hold Promise in Regenerative Medicine
As of May 26, 2023, Nasdaq-listed Celularity Inc. (NASDAQ:CELU) opened at $0.61 on Friday, trading well below its 52-week high ...
Celularitys FDA Approval for Investigational Bone Void Filler Product and Other Cell Therapies in the Pipeline
On April 3, 2023, Celularity, a biotechnology company that specializes in clinical-stage research and development of placental-derived allogeneic cell therapies, ...
Celularity Inc partners with AD Ports Group for exclusive distribution agreement in the Middle East
Celularity Inc. has recently announced an exclusive distribution agreement with AD Ports Group, a renowned logistics, industry, and trade facilitator. ...